Vaccines save millions of lives each year and are among the most
cost-effective health interventions developed.
Despite these great strides, there remains an urgent need to reach all
children and adults with life-saving vaccines. Immunizations avert an estimated 2.5 million deaths each
year around the world. However, an estimated 22.6 million infants worldwide are
still missing out on basic vaccines. Unreliable transportation systems
and storage facilities make it difficult to preserve high-quality vaccines that
require constant refrigeration.
Typical liquid vaccines can be particularly difficult as they must be stored at
lower than room temperature at all times. This is not possible in many parts of
the world, especially in developing countries. There is an urgent need for
technologies that can provide vaccines that are easily transportable and that
can remain viable for a longer period of time without refrigeration.
Researchers at the
University of New Mexico have developed a method for needle-free vaccination,
which can be administered orally or by the pulmonary route. In addition, this
formulation allows for an increased length of time that the vaccine remains
viable under non-refrigerated, ambient temperature conditions. These dry
powder vaccines can be delivered using a pill or a capsule and thus represents
a significant delivery improvement over existing injected liquid vaccines. Furthermore, the material used
to encapsulate these bacterial vaccines into a protective matrix is already FDA
STC has filed intellectual property on this exciting new technology and is currently exploring commercialization options. If you are interested in information about this or other technologies, please contact Arlene Mirabal at firstname.lastname@example.org or 505-272-7886.